Zogenix initiated with a Buy at BofA/Merrill. BofA/Merrill analyst Tazeen Ahmad initiated Zogenix with a Buy and $63 price target saying lead asset, ZX008, could become a best-in-class treatment for pediatric epilepsies with a focus on Dravet Syndrome. Ahmad said there is an unmet need and is modeling world-wide peak sales of $3.4B, higher than peak sales achieved by other anti-epileptic drugs and anticonvulsants.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.